Strategic Vision: A Global Pharma Company
Complex Generics and Biosimilars Opportunity
Opportunities exist in products with barriers to entry
Generics market offers opportunities in
First to market / first to file opportunities
Complex dosage forms like injectables, inhalation
Complex categories market size (Brand + Generics) US$ bn¹
With several biologics going off-patent, biosimilars
have a long way to go with new launches and
incremental penetration in US and EU
Top Biologics Global Sales US$ Bn²
882823220
10
90
83
70
65
60
50
Adalimumab
Pembrolizumab
Ustekinumab
Insulin Glargine
18.5
14.1
13.9
Etanercept
10.6
Insulin Aspart
9.8
40
28
24
13
9
10 11
10
Nivolumab
8.8
Infliximab
7.7
Insulin Lispro
7.5
8
Dupilumab
7.1
Daratumumab
6.3
Injectables
Inhalation Dermatology Ophthalmics
Others
Secukinumab
6.2
Bevacizumab
6.1
2017 2021
1. IQVIA MIDAS MAT Dec 2017 and Dec 2021
2. IQVIA MIDAS MAT Dec 2021
34.6
LUPIN
13View entire presentation